



22 May 2026

Vectus completes \$0.8 million placement to accelerate its VB0004 clinical trial work and other drug programmes

Vectus Biosystems Limited (ASX:VBS) (Vectus or the Company) is pleased to announce that it has received firm commitments from institutional and sophisticated investors to raise \$791,000, before costs, through a placement of 7,910,000 new fully paid ordinary shares at \$0.10 per share (Placement). For each Vectus share issued, the applicant shall receive a Vectus option exercisable at \$0.20 and the options will be issued following approval at the Company's next shareholder meeting (refer note below). The options will expire two years from the date of issue, if not exercised. The new shares to be issued under the Placement will rank *pari passu* with existing fully paid ordinary shares. Vectus will be utilising its placement capacity in accordance with ASX Listing Rule 7.1 for the issue of the 7,910,000 new fully paid ordinary shares.

The Placement was supported by a number of qualifying sophisticated investors, which do not include any related parties of the Company. New share quotation on ASX is expected to occur on or about 27 May 2026.

The net proceeds of the Placement will be used to accelerate the Phase IB clinical trial for VB0004, which targets the prevention and reversal of fibrosis in the lungs, heart and kidneys. Proceeds will also be used to advance Vectus' other emerging lead compounds and for working capital.

Gleneagle Securities (Aust) Pty Limited was the Lead Manager for the Placement.

The Company's Chairman, Dr Ronald Shnier, said:

"We are pleased with the support received for the Placement and Vectus will continue its work on its additional compounds to get them to lead status and move them towards human trials. A stronger balance sheet will underpin the Company's capabilities in pursuing clinical data on VB0004 and to advance its other drugs."

Ronald Shnier
Chairman

Tara Speranza
Chief Executive Officer and Chief Technology Officer

This announcement was authorised by the Board of Directors.

Note on Options

If the investor decides to exercise the options and convert them into shares within the first 12 months from the date of issue, those resulting shares cannot be sold to a retail investor on the market unless the company issues a Cleansing Notice at the exact time of exercise (under section 708A(5) of the Corporations Act), or the 12-month anniversary from the original option issue date has passed.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

Unit 5, Ground Floor, 26-34 Dunning Avenue, Rosebery NSW 2018 Australia

Telephone: +61 2 8344 1300, Facsimile: +61 2 9697 0944

Email: info@vectusbiosystems.com.au

Website: www.vectusbiosystems.com.au



About Vectus Biosystems Limited

The Company is developing treatments for fibrosis, including for four of the largest diseases in the fibrotic market, namely heart, kidney, lung and liver diseases. Since listing on the ASX in 2016, Vectus has concentrated on the development of the Company's lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 has progressed through a number of important milestones, including pharmaceutical scale-up and additional toxicity studies, its Human Phase Ia and Ib human trials of VB0004, and the advancement of other drugs in its library. This fits with the Company's strategy of developing, and carrying out early validation work on, its library of drug candidates to the point where they become commercially attractive to pharmaceutical partners.

For personal use only